InvestorsHub Logo
Followers 32
Posts 3331
Boards Moderated 0
Alias Born 08/31/2006

Re: None

Thursday, 09/28/2017 9:37:11 AM

Thursday, September 28, 2017 9:37:11 AM

Post# of 15819
Sep 26, 2017 Ladenburg Thalmann 2017 Healthcare Conference Presentation

http://files.shareholder.com/downloads/OPKO/5178707471x0x957689/D6720A48-1289-42FF-A8C8-E4B6AEEDAB65/OPKO_Health_Inc_September_2017.v2.pdf

UPCOMING MILESTONES
PROGRESS ACROSS MULTIPLE BUSINESS AREAS

Expand Rayaldee field sales force October 2017
SARM Phase 2 Initiate in 4Q17
Claros 1 PSA clinical study PMA filing 4Q17
Claros 1 testosterone clinical study Initiate 1H18
Oxyntomodulin Phase 2b Initiate 1H18
hGH-CTP Phase 3 Pediatric Enrollment ongoing
Rayaldee Stage 5 CKD Phase 2 Initiate 4Q17
AntagoNAT Dravet Phase 2b Initiate 4Q17
NK-1 Antagonist Pruritus Phase 2a Initiate 4Q17
Pediatric hgh-CTP registration study Initiated 3Q17
in Japan
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OPK News